Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024-12 · 262 (12) · 3787-3796
DOI: 10.1007/s00417-024-06569-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 08.07.2024. Verfasst von Ömer Özer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey. omerozer92@gmail.com. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Biomarkers, Retinal Diseases, Inflammation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nigde Omer Halisdemir University.
Abstract (Originalsprache)
Background
The aim of this study was to evaluate the clinical significance of blood-cell associated inflammation markers in patients with sickle cell disease (SCD) and sickle cell retinopathy (SCR).
Methods
Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune inflammation index (SIII), systemic inflammation response index (SIRI), systemic inflammation modulation index (SIMI) and aggregate systemic inflammation index (AISI) were calculated. This study included 45 healthy controls (Group 1) and 100 SCD (Group 2). Patients in Group 2 were then divided into two groups: without SCR (Group 3) and with SCR (Group 4), and patients with SCR (Group 4) were further divided into two groups: non-proliferative sickle cell retinopathy (NPSCR) (Group 5) and proliferative sickle cell retinopathy (PSCR) (Group 6).
Results
The mean values for NLR, PLR, SIII, SIRI, AISI, and SIMI were significantly higher in Group 2 compared to Group 1 ( p = 0.011 for NLR, p = 0.004 for SIII, and p < 0.001 for others). Furthermore, AISI and SIMI parameters demonstrated statistically significant discriminatory power to distinguish Group 5 from Group 6 ( p = 0.0016 and p = 0.0006, respectively).
Conclusion
Given the critical role of inflammatory mechanisms in the pathogenesis of SCD and its related complications, the assessment of blood-cell-associated inflammatory markers may present a pragmatic and advantageous approach to the clinical oversight and therapeutic intervention of SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey. omerozer92@gmail.com.
- Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, 51240, Turkey.
- Clinic of Internal Medicine, Gülnar State Hospital, Mersin, Turkey.
- Department of Biostatistics and Medical Informatics, Niğde Ömer Halisdemir University, Niğde, Turkey.
- Clinic of Ophthalmology, Tarsus State Hospital, Mersin, Turkey.
- Clinic of Ophthalmology, Mersin State Hospital, Mersin, Turkey.
Förderung
- Nigde Omer Halisdemir University
Zitieren
APA
Özer, Ö., Doğan, L., Baysal, Z., Basir, H., Çıftçı, A. T., Eröz, P., & Güçlü, E. S. (2024). Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 262(12), 3787-3796. https://doi.org/10.1007/s00417-024-06569-9
Vancouver
Özer Ö, Doğan L, Baysal Z, Basir H, Çıftçı AT, Eröz P, et al. Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024;262(12):3787-3796. doi:10.1007/s00417-024-06569-9
BibTeX
@article{zer2024,
author = {Özer, Ömer and Doğan, Levent and Baysal, Zeki and Basir, Hakan and Çıftçı, Ali Türker and Eröz, Pınar and Güçlü, Emin Serbülent},
title = {Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
volume = {262},
number = {12},
pages = {3787--3796},
doi = {10.1007/s00417-024-06569-9}
}
EUVIMED